Commissioning Famework for Biological Medicines
|Commissioning Famework for Biological Medicines (Including Biosimilar Medicines)|
|NHS Clinical Commissioners|
As the biosimilar market develops, increased competition between biological medicines has the potential to deliver significant savings of at least £200m to £300m per year by 2020/21 through increased uptake of the best value biologic medicine, including biosimilars. Such action will help the NHS to maximise the value for patients from the amount it spends on these medicines and enable much needed headroom for funding innovative treatments and/or improvements in pathways of care.
|Date of publication|
|To access the resource, click here.|